Diabetes can destroy nerves in the entire body. Diabetic neuropathy is very common problem of diabetes mellitus coldness, aching hands, legs and feet, muscle weakness in the feet and hands, and coldness to pain or changes in the temperature are the usual symptoms of diabetic neuropathy. Peripheral, focal, autonomic, and proximal neuropathy are the kinds of diabetic neuropathy. Amidst them, peripheral neuropathy is very common form in which feet and legs are impacted first then later by hands and arms. Diabetic neuropathy can be severely painful and can’t be cured. Amitriptyline Pregabalin, and citalopram are few first-line therapies for painful diabetic neuropathy.
The U.S. diabetic neuropathy market is expected to be evaluated at US$ 1,759.4 million in 2022 and is anticipated to show a CAGR of 5.2% over the predicted duration (2022-2030).
Request FREE Sample Report (Including Full TOC, Table & Figures) @
https://www.coherentmarketinsights.com/insight/request-sample/5356
Market Drivers:
Rising inanimate plans such as approvals of products from regulatory officials such as the U.S. FDA is anticipated to fuel the growth of the U.S. diabetic neuropathy market. For example, in December 2019, Averitas Pharma, Inc., declared that they had gained support from U.S. FDA for QUTENZA, the therapy of neuropathic pain linked with diabetic peripheral neuropathy of the legs in adults. QUTENZA is the first and only mild, non-systemic, non-opioid pain therapy for diabetic peripheral neuropathy. A unique local topical therapy with QUTENZA may offer up to a quarter of relief from the nerve pain.
Impact of Coronavirus
As the COVID-19 virus outbreak in December 2019, the disorder has spread to above 100 regions globally and the WHO had announced it a public health crisis on January 30, 2020.
COVID-19 can impact the economy in three main methods: by straightly impacting manufacture and need of medicines, by leading to interruptions in supply channels, and from its financial impact on organizations and financial markets. Owing to nationwide lockdowns, various economies, such as Saudi Arabia, China, India, U.A.E., Egypt, and others, are experiencing difficulties with respect to the transference of drugs from one place to other.
Anyhow, the COVID-19 epidemic had an effective effect on the U.S. diabetic neuropathy market owing to the rising threat of peripheral neuropathy from COVID-19. For example, as per the data published in March 2022, by WUSM, COVID-19 patients are severely at high threat of undergoing symptoms of peripheral neuropathy, such as aching, numbness and tingling in the hands and legs, which, further, enhanced the sales of neuropathic therapy medicines, hence effectively affecting the global diabetic neuropathy market growth.
Key Developments
Acquirement of inanimate growth plans such as approval of drugs from government officials such as the U.S. FDA is anticipated to fuel the U.S. diabetic neuropathy market. For example, in July 2019, Alembic Pharmaceuticals Limited, declared that they had gained a clearance from U.S. FDA for or Pregabalin tablets, an oral and extended-release capsules, which exhibited for management of neuropathic pain linked with diabetic peripheral neuropathy, administration of postherpetic neuralgia, adjunctive therapeutics for the therapy of partial-onset annexations in patients 17 years of age and older.
Market Restraints:
Expensive therapy of diabetic neuropathy in the U.S. is anticipated to hinder the growth of the U.S. diabetic neuropathy market during the predicted duration. For example, in February 2020, as per the data generated by NCBI, there is a considerable rise in health care costs amidst a large number of individuals with pDPN. The total median hospital expenses was US$ 16,795 in the first year after examining and patients with pDPN spent thrice as much on drugs.
Download PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/5356
Key Players
Key players involved in the U.S. diabetic neuropathy market are Lupin, Tissue Tech, Inc., Ionis Pharmaceuticals, NeuroMetrix, Inc., Eli Lilly and Company, Alembic Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Regenacy Pharmaceuticals, Inc., Novartis AG, Pfizer, Inc., GSK plc., Glenmark Pharmaceuticals Ltd., Abbott, and Averitas Pharma, Inc.
Reasons to buy this U.S. Diabetic Neuropathy Market Report
☑ It attempts an analysis of the competing scenario.
☑ The current and exceptional product revenue market.
☑ An in-depth data on the regional investigation and competitive landscape structure.
☑ It benefits in creating an awareness of the important key product segments.
☑ The marketing strategies, opportunities, and development factors are explained.
☑ U.S. Diabetic Neuropathy market size estimation and recent advancements in the industry are explained.
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/5356
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Impact Analysis
- Partnership and Collaboration Scenario
- Recent Product Launches and Approvals
- Market Trends
- Regulatory Scenario
- PEST Analysis
- Reimbursement Scenario
- Cost of therapy
- Brand Mapping
- Market Dynamics
- U.S. Diabetic Neuropathy Market – Impact of Coronavirus (Covid-19) Pandemic
- Overall Impact
- Impact on Supply and Demand
- COVID-19 Impact on the market
- U.S. Diabetic Neuropathy Market, By Drug, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Tricyclic Antidepressants
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Amitriptyline
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Nortyptyline
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Imipramine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Desipramine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Amitriptyline
- SSRI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Paroxetine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Citalopram
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Paroxetine
- Anticonvulsants
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Gabapentin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Pregabalin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Carbamazepine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Others (Oxcarbazepine, Topiramate and Others)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Gabapentin
- Opioids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Tramadol
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Tapentadol
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Oksikodon
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Tramadol
- SNRIs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Duloxetine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Duloxetine
- Other Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million
- Capsaicin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Lidocaine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Botilinum Toxin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Capsaicin
- Overview
- U.S. Diabetic Neuropathy Market, By Type, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Peripheral Neuropathy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Proximal Neuropathy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Autonomic Neuropathy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Focal Neuropathy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
- U.S. Diabetic Neuropathy Market, By Route of Administration, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Topical
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Injection (Intramuscular)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
- U.S. Diabetic Neuropathy Market, By Distribution Channel, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
- Competitive Landscape
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Glenmark Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lupin
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Regenacy Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alembic Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ionis Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- NeuroMetrix, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Tissue Tech, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Averitas Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Section
- Research Methodology
- About Us
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact us:
Mr. Shah
Coherent Market Insights
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com